The Baloch Liberation Army (BLA) asserted that its members killed at least seven Pakistani soldiers during a military ...

Atara Biotherapeutics Inc (NASDAQ:ATRA) saw its stock jump 7% following the U.S. Food and Drug Administration’s acceptance of ...

The FDA has accepted the resubmitted BLA for tabelecleucel (tab-cel), intended for the treatment of Epstein-Barr virus ...

Among reasons for the rejection, the agency cited a lack of US patient representation in the STARGLO trial assessing ...

The Baloch Liberation Army (BLA) has claimed responsibility for a series of coordinated attacks on Pakistani security forces ...

Replimune Group, Inc – a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies – ...

Tabelecleucel, an allogeneic, EBV-specific T-cell immunotherapy, works by targeting and eliminating EBV-infected cells.

The BLA took up arms against the Pakistani state due to what it considered the federal government’s “continuous misadventures”, which, it claimed, ...

The FDA's request stems from observations made during recent inspections of Ultragenyx's manufacturing facilities.

FDA issued Complete Response Letter Capricor plans to resubmit its BLA to include data from the ongoing Phase 3 HOPE-3 trial in Q3 2025 to continue pursuing the indication for the treatment of ...

Investing.com -- Atara Biotherapeutics Inc (NASDAQ: ATRA) stock surged 7% after the U.S. Food and Drug Administration (FDA) accepted the filing of its Biologics License Application (BLA) for ...